| Literature DB >> 30480360 |
Hyun Min Koh1, Dae Hyun Song1,2,3.
Abstract
BACKGROUND: Rab27A and Rab27B are the major components of vesicle fusion and trafficking in exosome secretion and play important roles in tumor progression and metastasis. In addition, Rab27A and Rab27B are associated with tumor prognosis. This study investigated the prognostic roles of Rab27A and Rab27B expression in patients with non-small cell lung cancer (NSCLC).Entities:
Keywords: Carcinoma; Rab27A; Rab27B; non-small cell; prognosis
Mesh:
Substances:
Year: 2018 PMID: 30480360 PMCID: PMC6360262 DOI: 10.1111/1759-7714.12919
Source DB: PubMed Journal: Thorac Cancer ISSN: 1759-7706 Impact factor: 3.500
Figure 1Rab27A and Rab27B expression in non‐small cell lung cancer. High expression of (a,b) Rab27A and (c,d) Rab27B in squamous cell carcinoma and adenocarcinoma, respectively (original magnification: 200×).
Clinicopathological patient data
| Data | Number (%) ( |
|---|---|
| Median age (years) | 66 |
| Male gender | 111 (83.5) |
| Smoking history | 86 (64.7) |
| Surgical procedure | |
| Lobectomy | 116 (87.2) |
| Bilobectomy or sleeve lobectomy | 3 (2.3) |
| Pneumonectomy | 14 (10.5) |
| Histologic type | |
| Squamous cell carcinoma | 96 (72.2) |
| Well‐differentiated | 15 |
| Moderately‐differentiated | 59 |
| Poorly‐differentiated | 22 |
| Adenocarcinoma | 37 (27.8) |
| Acinar | 15 |
| Solid | 6 |
| Papillary | 8 |
| Micropapillary | 3 |
| Lepidic | 3 |
| Mucinous | 2 |
| Tumor stage | |
| T1 | 45 (33.8) |
| T2 | 56 (42.1) |
| T3 | 21 (15.8) |
| T4 | 11 (8.3) |
| Lymph node metastasis | |
| N0 | 90 (67.7) |
| N1 | 40 (30.0) |
| N2 | 3 (2.3) |
| Distant metastasis | |
| M0 | 130 (97.7) |
| M1a | 3 (2.3) |
| Tumor node metastasis stage | |
| I | 57 (42.8) |
| II | 54 (40.6) |
| III | 19 (14.3) |
| IV | 3 (2.3) |
| Median survival (months) | 40 |
Smoking history was defined as ex‐smokers and current smokers.
Correlation of RAB27A and RAB27B expression with clinicopathological data
| RAB27A expression | RAB27B expression | |||||
|---|---|---|---|---|---|---|
| Data | Low expression | High expression |
| Low expression | High expression |
|
| Age | 0.360 | 0.906 | ||||
| < 65 | 25 (43.9) | 32 (56.1) | 44 (83.0) | 9 (17.0) | ||
| ≥ 65 | 27 (36.0) | 48 (64.0) | 57 (83.8) | 11 (16.2) | ||
| Gender | 0.007 | 0.002 | ||||
| Male | 49 (44.5) | 61 (55.5) | 89 (88.1) | 12 (11.9) | ||
| Female | 3 (13.6) | 19 (86.4) | 12 (60.0) | 8 (40.0) | ||
| Smoking | 0.637 | 0.218 | ||||
| Non‐smoker | 17 (37.0) | 29 (63.0) | 33 (78.6) | 9 (21.4) | ||
| Smoker | 35 (41.2) | 50 (58.8) | 68 (87.2) | 10 (12.8) | ||
| Surgery | 0.711 | 0.568 | ||||
| Lobectomy | 46 (40.0) | 69 (60.0) | 86 (82.7) | 18 (17.3) | ||
| Other | 6 (35.3) | 11 (64.7) | 15 (88.2) | 2 (11.8) | ||
| Histologic type | 0.009 | < 0.001 | ||||
| SQCC | 44 (46.3) | 51 (53.7) | 81 (92.0) | 7 (8.0) | ||
| ADC | 8 (21.6) | 29 (78.4) | 20 (60.6) | 13 (39.4) | ||
| Tumor stage | 0.320 | 0.981 | ||||
| T1,T2 | 37 (37.0) | 63 (63.0) | 76 (83.5) | 15 (16.5) | ||
| T3,T4 | 15 (46.9) | 17 (53.1) | 25 (83.3) | 5 (16.7) | ||
| Lymph node metastasis | 0.687 | 0.882 | ||||
| Absent | 34 (38.2) | 55 (61.8) | 69 (83.1) | 14 (16.9) | ||
| Present | 18 (41.9) | 25 (58.1) | 32 (84.2) | 6 (15.8) | ||
| Distant metastasis | 0.158 | 0.199 | ||||
| Absent | 52 (40.3) | 77 (59.7) | 100 (84.0) | 19 (16.0) | ||
| Present | 0 (0.0) | 3 (100.0) | 1 (50.0) | 1 (50.0) | ||
| TNM stage | 0.111 | 0.647 | ||||
| I, II | 40 (36.4) | 70 (63.6) | 85 (84.2) | 16 (15.8) | ||
| III, IV | 12 (54.5) | 10 (45.5) | 16 (80.0) | 4 (20.0) | ||
Other includes bilobectomy or sleeve lobectomy and pneumonectomy.
Values are presented as numbers (%).
ADC, adenocarcinoma; SQCC, squamous cell carcinoma; TNM, tumor node metastasis.
Figure 2Kaplan‐Meier survival analysis based on Rab27B expression in patients with squamous cell carcinoma (SQCC). The high‐expression group shows (a) significantly lower disease‐specific survival and (b) a tendency toward decreased disease‐free survival compared to those in the low‐expression group. () low expression (n = 81), and () high expression (n = 7).
Cox proportional hazards regression model of DFS and DSS in NSCLC patients (n = 133)
| Univariate analysis | Multivariate analysis | |||||||
|---|---|---|---|---|---|---|---|---|
| DFS | DSS | DFS | DSS | |||||
| Characteristic | HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
| HR (95% CI) |
|
| SQCC | ||||||||
| Age (< 65 vs. ≥ 65) | 1.402 (0.784–2.506) | 0.255 | 1.170 (0.635–2.157) | 0.614 | ||||
| Gender (male vs. female) | 0.824 (0.200–3.391) | 0.789 | 0.398 (0.055–2.895) | 0.363 | ||||
| Smoking (non‐smoker vs. smoker) | 0.644 (0.356–1.164) | 0.145 | 0.671 (0.355–1.266) | 0.218 | ||||
| TNM stage (I–II vs. III–IV) | 2.325 (1.208–4.476) | 0.012 | 2.060 (1.016–4.176) | 0.045 | 2.175 (1.124–4.208) | 0.021 | 1.968 (0.965–4.013) | 0.063 |
| Rab27B expression (low vs. high) | 1.789 (0.761–4.204) | 0.182 | 2.513 (1.053–6.000) | 0.038 | 1.909 (0.809–4.505) | 0.140 | 2.680 (1.116–6.437) | 0.027 |
| ADC | ||||||||
| Age (<65 vs. ≥65) | 0.934 (0.296–2.945) | 0.907 | 0.818 (0.195–3.428) | 0.784 | ||||
| Gender (male vs. female) | 0.736 (0.234–2.320) | 0.601 | 0.592 (0.141–2.484) | 0.474 | ||||
| Smoking (non‐smoker vs. smoker) | 0.918 (0.269–3.139) | 0.892 | 1.690 (0.422–6.764) | 0.459 | ||||
| TNM stage (I–II vs. III–IV) | 2.011 0.588–6.878) | 0.266 | 1.621 (0.327–8.047) | 0.554 | 2.456 (0.569–10.594) | 0.228 | 2.519 (0.480–13.228) | 0.275 |
| Rab27B expression (low vs. high) | 0.743 (0.186–2.972) | 0.675 | 0.947 (0.226–3.971) | 0.941 | 0.631 (0.152–2.627) | 0.527 | 0.804 (0.183–3.532) | 0.773 |
ADC, adenocarcinoma; CI, confidence interval; DFS, disease‐free survival; DSS, disease‐specific survival; HR, hazard ratio; NSCLC, non‐small cell lung cancer; SQCC, squamous cell carcinoma; TNM, tumor node metastasis.
Clinicopathological data of SQCC patients with high Rab27B expression (n = 7)
| Patient number | Gender/age | TNM stage | Tumor differentiation | Smoking history | Surgical method | DSS (months) | Mean DSS by TNM stage (months) |
|---|---|---|---|---|---|---|---|
| 1 | M/68 | IA3 | PD | Smoker | Lobectomy | 95 | 43.88 |
| 2 | M/66 | IB | MD | Smoker | Lobectomy | 27 | 47.61 |
| 3 | M/66 | IIA | MD | Smoker | Lobectomy | 29 | 45.29 |
| 4 | M/68 | IIA | PD | Smoker | Lobectomy | 14 | 45.29 |
| 5 | M/61 | IIB | MD | Non‐smoker | Pneumonectomy | 9 | 44.30 |
| 6 | M/72 | IIB | MD | Smoker | Lobectomy | 7 | 44.30 |
| 7 | M/71 | IIIA | MD | Smoker | Pneumonectomy | 9 | 25.71 |
DSS, disease‐specific survival; MD, moderately‐differentiated; PD, poorly‐differentiated; SQCC, squamous cell carcinoma; TNM, tumor node metastasis.